Phase 2 Placebo-controlled Randomized Trial of LACTIN-V (Lactobacillus Crispatus CTV-05) Among Women at High Risk of HIV Acquisition in Durban, South Africa

The purpose of this study is to assess the impact of LACTIN-V, a vaginally administered live biotherapeutic product (LBP) that contains the human L. crispatus CTV-05 strain, on the vaginal microbiome of Lactobacillus-deficient young women in the South African FRESH study who are at high risk for HIV acquisition.

开始日期2021-05-10

申办/合作机构

The University of California, San Francisco

[+5]

NCT03992534 / Unknown status临床1期IIT

Feasibility, Safety, Tolerance and Assessment of LACTIN-V Use in a Cohort of Pregnant Women at Risk of Preterm Birth

Preterm birth (PTB) is the primary cause of infant death worldwide. It has been shown that a vaginal microbiota deplete in Lactobacillus species is a risk factor for preterm labour. Conversely a vaginal microbiota dominated by Lactobacillus crispatus appears to be protective for these adverse outcomes. A wide range of 'over the counter' Lactobacillus spp. containing products targeted at 'vaginal health' and formulated for vaginal administration are available, but most of them do not contain vaginal species of Lactobacillus. The primary aim of this study is to determine whether vaginal supplementation with L. crispatus CTV-05 is associated with colonisation.

开始日期2019-09-16

申办/合作机构

Imperial College London

[+1]

NCT02766023 / Completed临床2期IIT

Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis

This Phase 2b trial is designed to provide a screening evaluation for the hypothesis that, following a 5-day treatment with MetroGel® to treat BV, L. crispatus CTV-05 (LACTIN-V, Osel, Inc.) administered at 2 x 10^9 cfu/dose using a vaginal applicator reduces the 12-week incidence of BV recurrence when compared to placebo. The primary objectives of this study are: 1) To estimate the efficacy of repeated doses of LACTIN-V (2 x 10^9 cfu/dose) as compared to placebo in preventing BV recurrence by 12 weeks following treatment of BV with MetroGel vaginal gel (MetroGel). 2) To assess the safety of LACTIN-V over 24 weeks by comparing the incidence of AEs between individuals randomized to LACTIN-V or placebo.

开始日期2016-06-03

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 CTV-05 相关的临床结果

登录后查看更多信息

100 项与 CTV-05 相关的转化医学

登录后查看更多信息

100 项与 CTV-05 相关的专利（医药）

登录后查看更多信息

项与 CTV-05 相关的文献（医药）

2024-08-06·Microbiology Spectrum

Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile

Article

作者: Liu, Rachel ; Cohen, Craig R ; Huibner, Sanja ; Hemmerling, Anke ; Castañeda, Gloria R ; Coburn, Bryan ; Miller, Steve ; Kaul, Rupert ; Kulikova, Maria ; Armstrong, Eric ; Crawford, Emily

ABSTRACT Vaginal colonization by fungi may elicit genital inflammation and enhance the risk of adverse reproductive health outcomes, such as HIV acquisition. Cross-sectional studies have linked fungi with an absence of bacterial vaginosis (BV), but it is unclear whether shifts in vaginal bacteria alter the abundance of vaginal fungi. Vaginal swabs collected following topical metronidazole treatment for BV during the phase 2b, placebo-controlled trial of LACTIN-V, a Lactobacillus crispatus -based live biotherapeutic, were assayed with semi-quantitative PCR for the relative quantitation of fungi and key bacterial species and multiplex immunoassay for immune factors. Vaginal fungi increased immediately following metronidazole treatment for BV (adjusted P = 0.0006), with most of this increase attributable to Candida albicans . Vaginal fungi were independently linked to elevated levels of the proinflammatory cytokine interleukin (IL) 17A, although this association did not remain significant after correcting for multiple comparisons. Fungal relative abundance by semi-quantitative PCR returned to baseline levels within 1 month of metronidazole treatment and was not affected by LACTIN-V or placebo administration. Fungal abundance was positively associated with Lactobacillus species, negatively associated with BV-associated bacteria, and positively associated with a variety of proinflammatory cytokines and chemokines, including IL-17A, during and after study product administration. Antibiotic treatment for BV resulted in a transient expanded abundance of vaginal fungi in a subset of women which was unaffected by subsequent administration of LACTIN-V. Vaginal fungi were positively associated with Lactobacillus species and IL-17A and negatively associated with BV-associated bacteria; these associations were most pronounced in the longer-term outcomes. IMPORTANCE Vaginal colonization by fungi can enhance the risk of adverse reproductive health outcomes and HIV acquisition, potentially by eliciting genital mucosal inflammation. We show that standard antibiotic treatment for bacterial vaginosis (BV) results in a transient increase in the absolute abundance of vaginal fungi, most of which was identified as Candida albicans . Vaginal fungi were positively associated with proinflammatory immune factors and negatively associated with BV-associated bacteria. These findings improve our understanding of how shifts in the bacterial composition of the vaginal microbiota may enhance proliferation by proinflammatory vaginal fungi, which may have important implications for risk of adverse reproductive health outcomes among women.

2024-06-01·Sexually Transmitted Diseases

Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease

Article

作者: Cohen, Craig R. ; Armstrong, Eric ; Hemmerling, Anke ; Wierzbicki, Michael R.

ObjectivesLive biotherapeutic products (LBPs) containing vaginal Lactobacillus crispatus are promising adjuvant treatments to prevent recurrent bacterial vaginosis (BV) but may depend on the success of initial antibiotic treatment.MethodsA post hoc analysis of data collected during the phase 2b LACTIN-V randomized control trial (L. crispatus CTV-05) explored the impact of clinical BV cure defined as Amsel criteria 0 of 3 (excluding pH, per 2019 Food and Drug Administration guidance) 2 days after completion of treatment with vaginal metronidazole gel on the effectiveness of an 11-week LACTIN-V dosing regimen to prevent BV recurrence by 12 and 24 weeks.ResultsAt enrollment, 88% of participants had achieved postantibiotic clinical BV cure. The effect of LACTIN-V on BV recurrence compared with placebo differed by initial clinical BV cure status. The LACTIN-V to placebo risk ratio of BV recurrence by 12 weeks was 0.56 (95% confidence interval, 0.35–0.77) among participants with initial clinical BV cure after metronidazole treatment and 1.34 (95% confidence interval, 0.47–2.23) among participants without postantibiotic clinical BV cure. Among women receiving LACTIN-V, those who had achieved postantibiotic clinical BV cure at enrollment reached higher levels of detectable L. crispatus CTV-05 compared with women failing to achieve postantibiotic clinical BV cure.ConclusionsLACTIN-V seems to only decrease BV recurrence in women with clinical cure of BV after initial antibiotic treatment. Future trials of LBPs should consider limiting enrollment to these women.

2023-04-14·Beneficial Microbes

Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial

Article

作者: Smidt, I ; Saare, M ; Le, D D ; Piiskop, S ; Ausmees, K ; Jaagura, M ; Kõljalg, S ; Štšepetova, J ; Salumets, A ; Mändar, R ; Rööp, T ; Tamm, H ; Sõerunurk, G

Health of reproductive tract is tightly associated with balance of microbial communities in this area. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) represent common disturbances of vaginal communities. Vaginal discharge due to BV or VVC is a very frequent reason for visiting gynaecologist. We aimed to evaluate the impact of the novel evidence-based probiotics on BV and VVC patients. The study group included 89 BV and 93 VVC patients (aged 18-50 years) who were recruited into randomised double-blind placebo-controlled two-arm parallel trial. The patients of each diagnosis group received oral or vaginal probiotic capsules, or placebo capsules during 3 months. A probiotic capsule contained two (DSM32717 and DSM32720, in case of BV) or three (DSM32720, DSM32718 and DSM32716, in case of VVC) Lactobacillus crispatus strains. Vaginal, intestinal and general health was monitored weekly by questionnaire. Blood analyses were done in the beginning and at the end of trial. Vaginal samples were collected monthly, microscopic and molecular analyses were performed. The study revealed that both oral and vaginal capsules reduced the signs and symptoms in BV patients. Remarkable improvement was noted in Nugent score, amount and smell of discharge, but also in itching/irritation. Consumption of vaginal probiotics significantly increased the lactobacilli counts in their vagina while mean proportion of some BV-related bacteria decreased. In VVC patients, both oral and vaginal capsules lowered the combined score of two most important symptoms, amount of discharge and itching/irritation. In conclusion, the novel formulations of evidence-based well-focused probiotic L. crispatus strains are effective against BV and VVC being suitable for both vaginal and oral administration.Clinical trial registration: ISRCTN34840624, BioMed Central

项与 CTV-05 相关的新闻（医药）

2024-09-09

·Pharmaceutical Technology

EASD24: PolTREG’s T-cell therapy shows long-term remission in type 1 diabetes

PolTREG plans to start a pivotal Phase II/III trial of PTG-007 for the treatment of type 1 diabetes and is pursuing partnership funding. Image Credit: Anatoliy Cherkas / Shutterstock. PolTREG’s has presented positive long-term data for its cell therapy, PTG-007, showing that the therapy induced clinical remission for type 1 diabetes for up to 12 years. The follow-up data from 54 patients with early-onset type 1 diabetes who took part in Phase I and II trials was presented at the European Association for the Study of Diabetes (EASD) taking place from 9-13 September in Spain. In light of the positive data, the Polish company will start a pivotal Phase II/III trial of PTG-007 for the treatment of type 1 diabetes and is pursuing partnership funding. “Today’s results are extremely encouraging and show that some patients remain in clinical remission for up to 12 years after initial treatment,” said Professor Piotr Trzonkowski, PolTREG’s CEO. “This makes us very eager to launch a pivotal study of PTG-007 as soon as we find a suitable partner.” The 54 patients with early-onset type 1 diabetes were followed for 7-12 years after receiving initial treatment as part of Phase I and Phase II trials. The study showed that a “proportion of patients” remained insulin-independent up to 18 to 24 months after treatment. See Also: LACTIN-V by Osel for Human Papillomavirus Infections: Likelihood of Approval Cadisegliatin by VTv Therapeutics for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval Additionally, some of the patients remained in clinical remission for 7-12 years after being treated with PTG-007. The trial defined clinical remission as having a low need for external insulin, while retaining proper metabolic/glycaemia control. The study also found that the “best results” were seen in patients who received the combination therapy of Treg therapy and Roche and Biogen ’s anti-CD20 treatment Rituxan (rituximab). The company plans to release detailed data and publish the results in a peer-reviewed scientific publication. PolTREG plans to initiate a Phase II trial evaluating PTG-007 in patients with presymptomatic type 1 diabetes. Cell therapies as a treatment for type 1 diabetes are gaining popularity. Last year saw the US Food and Drug Administration (FDA) approving the first cell therapy, CellTrans’s Lantidra (donislecel) for the treatment of type 1 diabetes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

细胞疗法临床结果临床1期临床2期基因疗法

2024-09-09

·Pharmaceutical Technology

Epsilogen secures additional funds in Series B for cancer treatment

The funds will support the trial of MOv18 IgE to potentially treat platinum-resistant ovarian cancer. Credit: Jo Panuwat D/Shutterstock. Epsilogen has completed a Series B expansion financing round, raising £12.5m ($16.4m) to progress the development of its immunoglobulin E (IgE) antibodies for cancer treatment. The investment was sourced entirely from existing backers British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund and ALSA Ventures. The latest funding takes the total raised in the Series B financing round to £43.25m. The funds will primarily support the clinical proof of concept for MOv18 IgE, the company’s leading asset, in a Phase Ib trial targeting platinum-resistant ovarian cancer. MOv18 IgE, a therapeutic IgE antibody, is designed to target the folate receptor alpha (FRα) which is prevalent in various cancers. See Also: LACTIN-V by Osel for Human Papillomavirus Infections: Likelihood of Approval Cadisegliatin by VTv Therapeutics for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval The Phase Ib trial of MOv18 IgE will have dose escalation and expansion parts, enrolling patients with FRα-positive PROC who have undergone up to four previous treatments. The trial follows a Phase I study where MOv18 IgE showed safety, tolerability and initial signs of clinical activity. MOv18 IgE’s unique mechanism of action is different from that of other clinical agents, due to its high-affinity binding to FcεR1 that promotes immunosurveillance and robust tumour cell destruction by myeloid cells. IgE antibodies have the potential to alter the tumour immune microenvironment, making it more pro-inflammatory, which results in higher levels of activated T cells and macrophages within the tumour, enhancing its destruction. Established in 2017, Epsilogen is a spin-out from King’s College London, UK. Its CEO Tim Wilson stated: “We are delighted to have received strong continued support from our existing investors, and we thank them. “The promise of IgE to treat cancer is based upon its unique mechanism of action and MOv18 IgE is the first ever to be tested in man. Everything is ready for phase Ib initiation which will occur shortly and we look forward to reporting progress from the trial.”

临床1期临床申请临床2期免疫疗法

2024-09-09

·Pharmaceutical Technology

Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug

In Phase IIb trial, the product provided substantial pain relief in osteoarthritis knee pain patients. Credit: VPLAB/Shutterstock. Sun Pharmaceutical Industries (Sun Pharma) and Moebius Medical have received fast track designation (FTD) from the US Food and Drug Administration (FDA) for MM-II (Large Liposomes of DPPC [dipalmitoylphosphatidylcholine] and DMPC [1,2‐dimyristoyl‐sn‐glycero‐3‐phosphocholine]), a non-opioid treatment for osteoarthritis knee pain. Osteoarthritis is a common chronic joint disease marked by the deterioration of joint cartilage. The FTD aims to expedite the development and review of treatments for serious conditions with unmet medical needs. This programme will accelerate the availability of new medicines that could significantly improve patient outcomes. Sun Pharma and Moebius will benefit from more frequent communication with the FDA and the possibility of an expedited approval process. See Also: LACTIN-V by Osel for Human Papillomavirus Infections: Likelihood of Approval Cadisegliatin by VTv Therapeutics for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval Moebius Medical CEO Moshe Weinstein stated: “This fast track designation, which will enable the FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II and follows our recently released Phase IIb data, which showed MM-II’s potential to provide effective and durable treatment for patients with knee pain of osteoarthritis.” MM-II is based on a technology involving large liposomes composed of DPPC and DMPC, designed to reduce joint friction and wear, thereby alleviating pain. The potential of MM-II was demonstrated in a Phase IIb clinical trial (NCT04506463), where a single 3ml intra-articular injection provided substantial pain relief compared to a placebo for up to 26 weeks. The companies are now preparing for confirmatory Phase III clinical trials to further evaluate the efficacy and safety of MM-II. Sun Pharma Global Development head and senior vice-president Marek Honczarenko stated: “As we enter Phase III development, we are very encouraged by the FDA’s decision to grant fast track designation to MM-II and recognise its potential to fill an unmet medical need for patients suffering from osteoarthritis.”

临床2期快速通道临床结果临床3期

100 项与 CTV-05 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌性阴道炎	临床3期	美国	Osel, Inc.	2022-07-22
HIV感染	临床2期	南非	Osel, Inc.	2021-05-10
早产	临床1期	美国	Osel, Inc.	2022-07-22
泌尿道感染	临床前	美国	University of Washington	2015-08-18
念珠菌病	临床前	美国	Osel, Inc.	2011-08-31
女性生殖道感染	临床前	美国	The Medicines Co.	2000-08-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05022212 (CTgov)	临床2期	HIV感染 \| 细菌性阴道炎	45	LACTIN-V (LACTIN-V)	遞顧鏇築鹽衊鹽壓醖窪(鹹製壓襯鬱選構廠糧鏇) = 衊遞顧壓獵夢鏇顧顧鹹遞範襯廠憲餘選築糧獵 (築廠醖鏇積願遞鹽膚網, 繭餘鹹願艱鏇製遞壓範 ~ 願遞繭餘築醖憲淵遞窪) 更多	-	2024-08-13
				Placebo (Placebo)	遞顧鏇築鹽衊鹽壓醖窪(鹹製壓襯鬱選構廠糧鏇) = 艱範鬱淵製鹹選襯淵餘遞範襯廠憲餘選築糧獵 (築廠醖鏇積願遞鹽膚網, 艱壓鑰衊鹽餘膚鏇獵醖 ~ 憲醖鏇襯鏇窪夢衊構顧) 更多
NCT03151967 (CTgov)	临床2/3期	泌尿道感染	27	Lactobacillus crispatus CTV-05 (Applicator With LACTIN-V Treatment)	鏇夢蓋繭餘廠鏇膚醖繭(鏇窪顧鹹齋壓鹽選鏇膚) = 積構觸艱鏇製網夢襯鏇醖淵襯選衊遞襯衊願簾 (鏇遞繭築遞夢糧鬱鹽壓, 築鬱選糧艱鑰淵鹽餘範 ~ 簾鬱選壓願網簾糧築衊) 更多	-	2023-03-01
				Placebo (Applicator With Placebo)	鏇夢蓋繭餘廠鏇膚醖繭(鏇窪顧鹹齋壓鹽選鏇膚) = 廠蓋夢窪蓋築蓋簾糧顧醖淵襯選衊遞襯衊願簾 (鏇遞繭築遞夢糧鬱鹽壓, 餘襯獵鬱餘窪鹽糧夢獵 ~ 淵簾構窪顧襯選膚壓鹹) 更多
NCT02766023 (Pubmed) 人工标引	临床2期	细菌性阴道炎	228	Lactin-V	蓋憲範構製夢繭繭積蓋(繭積淵觸衊積鏇夢窪簾) = 製鏇淵選繭襯網餘醖積夢衊膚窪廠鬱艱繭簾餘 (餘鏇醖齋衊蓋壓衊齋遞 ) 更多	积极	2020-05-14
				Placebo	蓋憲範構製夢繭繭積蓋(繭積淵觸衊積鏇夢窪簾) = 夢淵艱遞鏇築淵選膚繭夢衊膚窪廠鬱艱繭簾餘 (餘鏇醖齋衊蓋壓衊齋遞 )
NCT02766023 (CTgov)	临床2期	细菌性阴道炎	228	Metronidazole+Lactobacillus crispatus CTV-05 (LACTIN-V)	襯鏇窪膚壓憲鹽築鹹艱(餘繭夢鏇鏇襯糧顧襯廠) = 壓觸衊鹹餘遞築餘觸壓衊觸顧夢築鹽網膚獵選 (窪繭鹽襯艱鏇衊襯顧餘, 壓範窪簾餘醖夢遞窪壓 ~ 膚獵憲窪廠艱蓋襯繭遞) 更多	-	2020-02-11
				Placebo+Metronidazole (Placebo)	襯鏇窪膚壓憲鹽築鹹艱(餘繭夢鏇鏇襯糧顧襯廠) = 膚衊範糧衊觸襯積蓋夢衊觸顧夢築鹽網膚獵選 (窪繭鹽襯艱鏇衊襯顧餘, 鹽願願願積衊壓廠壓夢 ~ 鹽夢醖壓壓構鹽鏇遞襯) 更多
NCT00305227 (CTgov)	临床2期	泌尿道感染	100	Lactin-V (Lactin-V)	構壓簾膚鬱淵蓋繭構膚(鏇糧觸築觸鏇範淵遞願) = 願願齋觸廠醖築窪鹹艱範壓餘構製觸鏇構觸遞 (觸範製醖簾鬱窪獵顧選, 簾鬱鏇積壓範壓簾獵簾 ~ 簾夢繭繭壓艱壓構獵鹹) 更多	-	2014-07-04
				Placebo (Placebo)	構壓簾膚鬱淵蓋繭構膚(鏇糧觸築觸鏇範淵遞願) = 膚蓋窪鑰遞鬱選齋範選範壓餘構製觸鏇構觸遞 (觸範製醖簾鬱窪獵顧選, 餘製遞選簾醖窪壓憲簾 ~ 廠艱獵糧積鹽願簾獵糧) 更多
NCT00305227 (Pubmed \| Clin Infect Dis)	临床2期	泌尿道感染	100	Lactin-V	醖願鬱鹽鹹鑰網簾顧簾(膚廠積觸齋衊簾壓餘壓) = 夢顧鬱觸構衊衊範願齋窪構鹹淵鹽糧鑰衊齋膚 (淵顧糧淵鑰膚鑰願餘獵 )	积极	2011-05-01
				Lactobacillus crispatus probiotic (Placebo)	醖願鬱鹽鹹鑰網簾顧簾(膚廠積觸齋衊簾壓餘壓) = 積壓膚鬱遞願窪鏇遞壓窪構鹹淵鹽糧鑰衊齋膚 (淵顧糧淵鑰膚鑰願餘獵 )